{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T01:11:49Z","timestamp":1794705109517,"version":"4.9.1"},"reference-count":52,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100016198","name":"Idorsia Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016198","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.ymgme.2024.108556","type":"journal-article","created":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T17:58:00Z","timestamp":1722448680000},"page":"108556","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Clinical and preclinical insights into high-dose ambroxol therapy for Gaucher disease type 2 and 3: A comprehensive systematic review"],"prefix":"10.1016","volume":"143","author":[{"given":"Bibiche","family":"den Hollander","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoang Lan","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora L.","family":"Swart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hennie","family":"Bikker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla E.M.","family":"Hollak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion M.","family":"Brands","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ymgme.2024.108556_bb0005","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S0950-3536(97)80031-5","article-title":"Gaucher\u2019s disease: past, present and future","volume":"10","author":"Brady","year":"1997","journal-title":"Baillieres Clin. Haematol."},{"issue":"18","key":"10.1016\/j.ymgme.2024.108556_bb0010","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1001\/archinte.160.18.2835","article-title":"The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease","volume":"160","author":"Charrow","year":"2000","journal-title":"Arch. Intern. Med."},{"issue":"Suppl. 2","key":"10.1016\/j.ymgme.2024.108556_bb0015","article-title":"Gaucher disease: understanding the molecular pathogenesis of sphingolipidoses","volume":"24","author":"Cox","year":"2001","journal-title":"J. Inherit. Metab. Dis."},{"issue":"7","key":"10.1016\/j.ymgme.2024.108556_bb0020","doi-asserted-by":"crossref","first-page":"417","DOI":"10.2165\/00128072-200204070-00001","article-title":"Gaucher disease: pediatric concerns","volume":"4","author":"Elstein","year":"2002","journal-title":"Paediatr. Drugs"},{"issue":"240","key":"10.1016\/j.ymgme.2024.108556_bb0025","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008659","article-title":"Macrophage models of Gaucher disease for evaluating disease pathogenesis and candidate drugs","volume":"6","author":"Aflaki","year":"2014","journal-title":"Sci. Transl. Med."},{"issue":"9645","key":"10.1016\/j.ymgme.2024.108556_bb0030","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0140-6736(08)61522-6","article-title":"Phenotype, diagnosis, and treatment of Gaucher\u2019s disease","volume":"372","author":"Grabowski","year":"2008","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ymgme.2024.108556_bb0035","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18020441","article-title":"A review of Gaucher disease pathophysiology, clinical presentation and treatments","volume":"18","author":"Stirnemann","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymgme.2024.108556_bb0040","first-page":"73","article-title":"Characteristics of 26 patients with type 3 Gaucher disease: a descriptive analysis from the Gaucher outcome survey","volume":"14","author":"Schwartz","year":"2018","journal-title":"Mol. Genet. Metab. Rep."},{"issue":"1","key":"10.1016\/j.ymgme.2024.108556_bb0045","first-page":"7","article-title":"Gaucher disease: new expanded classification emphasizing neurological features","volume":"13","author":"Alaei","year":"2019","journal-title":"Iran J. Child Neurol."},{"issue":"9","key":"10.1016\/j.ymgme.2024.108556_bb0050","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1177\/1060028013500469","article-title":"Gaucher disease and its treatment options","volume":"47","author":"Bennett","year":"2013","journal-title":"Ann. Pharmacother."},{"issue":"1","key":"10.1016\/j.ymgme.2024.108556_bb0055","doi-asserted-by":"crossref","DOI":"10.3390\/diseases5010010","article-title":"The spectrum of neurological manifestations associated with Gaucher disease","volume":"5","author":"Roshan Lal","year":"2017","journal-title":"Diseases"},{"issue":"0 1","key":"10.1016\/j.ymgme.2024.108556_bb0060","first-page":"72","article-title":"Gaucher disease: the metabolic defect, pathophysiology, phenotypes and natural history","volume":"12 Suppl 1","author":"Baris","year":"2014","journal-title":"Pediatr. Endocrinol. Rev."},{"issue":"1\u20132","key":"10.1016\/j.ymgme.2024.108556_bb0065","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s004399900075","article-title":"The frequency of lysosomal storage diseases in the Netherlands","volume":"105","author":"Poorthuis","year":"1999","journal-title":"Hum. Genet."},{"issue":"4","key":"10.1016\/j.ymgme.2024.108556_bb0070","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s10545-009-9009-6","article-title":"Neuronopathic Gaucher disease: demographic and clinical features of 131 patients enrolled in the international collaborative Gaucher group neurological outcomes subregistry","volume":"33","author":"Tylki-Szyma\u0144ska","year":"2010","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2024.108556_bb0075","series-title":"Gaucher disease type 2: Orphanet","author":"Dr Nadia BELMATOUG DJS","year":"2012"},{"key":"10.1016\/j.ymgme.2024.108556_bb0080","series-title":"Gaucher Disease. The Online Metabolic and Molecular Bases of Inherited Disease","author":"Grabowski","year":"2019"},{"issue":"6","key":"10.1016\/j.ymgme.2024.108556_bb0085","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/1873-3468.12104","article-title":"Lysosomal glycosphingolipid catabolism by acid ceramidase: formation of glycosphingoid bases during deficiency of glycosidases","volume":"590","author":"Ferraz","year":"2016","journal-title":"FEBS Lett."},{"issue":"4","key":"10.1016\/j.ymgme.2024.108556_bb0090","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S1096-7192(02)00117-8","article-title":"Glucosylsphingosine accumulation in tissues from patients with Gaucher disease: correlation with phenotype and genotype","volume":"76","author":"Orvisky","year":"2002","journal-title":"Mol. Genet. Metab."},{"issue":"2\u20133","key":"10.1016\/j.ymgme.2024.108556_bb0095","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s10545-006-0272-5","article-title":"Substrate reduction therapy of glycosphingolipid storage disorders","volume":"29","author":"Aerts","year":"2006","journal-title":"J. Inherit. Metab. Dis."},{"issue":"4","key":"10.1016\/j.ymgme.2024.108556_bb0100","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00431-012-1771-z","article-title":"Revised recommendations for the management of Gaucher disease in children","volume":"172","author":"Kaplan","year":"2013","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.ymgme.2024.108556_bb0105","author":"Sanofi"},{"issue":"50","key":"10.1016\/j.ymgme.2024.108556_bb0110","doi-asserted-by":"crossref","first-page":"21665","DOI":"10.1073\/pnas.1014376107","article-title":"Decreased glucocerebrosidase activity in Gaucher disease parallels quantitative enzyme loss due to abnormal interaction with TCP1 and c-Cbl","volume":"107","author":"Lu","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"35","key":"10.1016\/j.ymgme.2024.108556_bb0115","doi-asserted-by":"crossref","first-page":"23502","DOI":"10.1074\/jbc.M109.012393","article-title":"Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease","volume":"284","author":"Maegawa","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymgme.2024.108556_bb0120","article-title":"Effect of Ambroxol chaperone therapy on Glucosylsphingosine (Lyso-Gb1) levels in two Canadian patients with type 3 Gaucher disease","volume":"20","author":"Charkhand","year":"2019","journal-title":"Mol. Genet. Metab. Rep."},{"issue":"3","key":"10.1016\/j.ymgme.2024.108556_bb0125","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/acn3.292","article-title":"Ambroxol chaperone therapy for neuronopathic Gaucher disease: a pilot study","volume":"3","author":"Narita","year":"2016","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"1","key":"10.1016\/j.ymgme.2024.108556_bb0130","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/jha2.852","article-title":"The use of Ambroxol for the treatment of Gaucher disease: a systematic review","volume":"5","author":"Abelleyra Lastoria","year":"2024","journal-title":"EJHaem"},{"key":"10.1016\/j.ymgme.2024.108556_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijsu.2021.105906","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"88","author":"Page","year":"2021","journal-title":"Int. J. Surg."},{"key":"10.1016\/j.ymgme.2024.108556_bb0140","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.907317","article-title":"Promising effect of high dose ambroxol treatment on neurocognition and motor development in a patient with neuropathic Gaucher disease 2","volume":"13","author":"Aries","year":"2022","journal-title":"Front. Neurol."},{"issue":"2","key":"10.1016\/j.ymgme.2024.108556_bb0145","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1136\/jmedgenet-2019-106132","article-title":"Pharmacologic properties of high-dose ambroxol in four patients with Gaucher disease and myoclonic epilepsy","volume":"57","author":"Kim","year":"2020","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2024.108556_bb0150","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ejpn.2021.03.013","article-title":"Early initiation of ambroxol treatment diminishes neurological manifestations of type 3 Gaucher disease: a long-term outcome of two siblings","volume":"32","author":"Ramad\u017ea","year":"2021","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"10.1016\/j.ymgme.2024.108556_bb0155","article-title":"In vitro and in vivo effects of Ambroxol chaperone therapy in two Italian patients affected by neuronopathic Gaucher disease and epilepsy","volume":"25","author":"Ciana","year":"2020","journal-title":"Mol. Genet. Metab. Rep."},{"issue":"2","key":"10.1016\/j.ymgme.2024.108556_bb0160","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.bcmd.2012.10.007","article-title":"Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase","volume":"50","author":"Bendikov-Bar","year":"2013","journal-title":"Blood Cells Mol. Dis."},{"issue":"1","key":"10.1016\/j.ymgme.2024.108556_bb0165","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bcmd.2010.10.012","article-title":"Characterization of the ERAD process of the L444P mutant glucocerebrosidase variant","volume":"46","author":"Bendikov-Bar","year":"2011","journal-title":"Blood Cells Mol. Dis."},{"issue":"11","key":"10.1016\/j.ymgme.2024.108556_bb0170","first-page":"3750","article-title":"Individualized screening for chaperone activity in Gaucher disease using multiple patient derived primary cell lines","volume":"10","author":"Ivanova","year":"2018","journal-title":"Am. J. Transl. Res."},{"issue":"10","key":"10.1016\/j.ymgme.2024.108556_bb0175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0247211","article-title":"Cellular and biochemical response to chaperone versus substrate reduction therapies in neuropathic Gaucher disease","volume":"16","author":"Ivanova","year":"2021","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.ymgme.2024.108556_bb0180","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.braindev.2012.05.008","article-title":"The chaperone activity and toxicity of ambroxol on Gaucher cells and normal mice","volume":"35","author":"Luan","year":"2013","journal-title":"Brain and Development"},{"issue":"7","key":"10.1016\/j.ymgme.2024.108556_bb0185","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23073536","article-title":"Mechanistic insight into the mode of action of acid \u03b2-glucosidase enhancer ambroxol","volume":"23","author":"Pantoom","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymgme.2024.108556_bb0190","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.parkreldis.2021.02.003","article-title":"Ambroxol increases glucocerebrosidase (GCase) activity and restores GCase translocation in primary patient-derived macrophages in Gaucher disease and Parkinsonism","volume":"84","author":"Kopytova","year":"2021","journal-title":"Parkinsonism Relat. Disord."},{"issue":"9","key":"10.1016\/j.ymgme.2024.108556_bb0195","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1002\/stem.1732","article-title":"Gaucher iPSC-derived macrophages produce elevated levels of inflammatory mediators and serve as a new platform for therapeutic development","volume":"32","author":"Panicker","year":"2014","journal-title":"Stem Cells"},{"issue":"9","key":"10.1016\/j.ymgme.2024.108556_bb0200","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8091420","article-title":"Drosophila melanogaster mutated in its GBA1b ortholog recapitulates neuronopathic Gaucher disease","volume":"8","author":"Cabasso","year":"2019","journal-title":"J. Clin. Med."},{"issue":"5","key":"10.1016\/j.ymgme.2024.108556_bb0205","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/ana.24790","article-title":"Ambroxol effects in glucocerebrosidase and \u03b1-synuclein transgenic mice","volume":"80","author":"Migdalska-Richards","year":"2016","journal-title":"Ann. Neurol."},{"issue":"8","key":"10.1016\/j.ymgme.2024.108556_bb0210","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0069147","article-title":"Expression of human Gaucher disease gene GBA generates neurodevelopmental defects and ER stress in Drosophila eye","volume":"8","author":"Suzuki","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2024.108556_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcmd.2019.102402","article-title":"Early initiation of high-dose oral ambroxol in combination with enzyme replacement therapy in a neuropathic Gaucher infant","volume":"81","author":"Chu","year":"2020","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.ymgme.2024.108556_bb0220","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.bcmd.2016.12.001","article-title":"The additive effect on the antiepileptic treatment of ambroxol in type 3 Gaucher patient. The early observation","volume":"68","author":"Pawlinski","year":"2018","journal-title":"Blood Cells Mol. Dis."},{"issue":"11","key":"10.1016\/j.ymgme.2024.108556_bb0225","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1007\/s00330-013-2924-9","article-title":"Proton MR spectroscopy of the brain in children with neuronopathic Gaucher\u2019s disease","volume":"23","author":"Razek","year":"2013","journal-title":"Eur. Radiol."},{"issue":"3","key":"10.1016\/j.ymgme.2024.108556_bb0230","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ymgme.2004.04.011","article-title":"Neuropathology provides clues to the pathophysiology of Gaucher disease","volume":"82","author":"Wong","year":"2004","journal-title":"Mol. Genet. Metab."},{"issue":"5","key":"10.1016\/j.ymgme.2024.108556_bb0235","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1023\/B:BOLI.0000042959.44318.7c","article-title":"Correlation between enzyme activity and substrate storage in a cell culture model system for Gaucher disease","volume":"27","author":"Schueler","year":"2004","journal-title":"J. Inherit. Metab. Dis."},{"issue":"7","key":"10.1016\/j.ymgme.2024.108556_bb0240","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1002\/ajh.27302","article-title":"A 10-year follow-up of high-dose ambroxol treatment combined with enzyme replacement therapy for neuropathic Gaucher disease","volume":"99","author":"Hwang","year":"2024","journal-title":"Am. J. Hematol."},{"issue":"4","key":"10.1016\/j.ymgme.2024.108556_bb0245","doi-asserted-by":"crossref","DOI":"10.1002\/mgg3.2427","article-title":"Rapid and long-lasting efficacy of high-dose ambroxol therapy for neuronopathic Gaucher disease: a case report and literature review","volume":"12","author":"Higashi","year":"2024","journal-title":"Mol. Genet. Genomic Med."},{"issue":"11","key":"10.1016\/j.ymgme.2024.108556_bb0250","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0079732","article-title":"Glucosylsphingosine is a highly sensitive and specific biomarker for primary diagnostic and follow-up monitoring in Gaucher disease in a non-Jewish, Caucasian cohort of Gaucher disease patients","volume":"8","author":"Rolfs","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2024.108556_bb0255","series-title":"Summary of Product Characteristics Ambroxol","author":"Authority HPR","year":"2016"},{"issue":"10","key":"10.1016\/j.ymgme.2024.108556_bb0260","first-page":"18744","article-title":"Pharmacokinetics of ambroxol and clenbuterol tablets in healthy Chinese volunteers","volume":"8","author":"Yang","year":"2015","journal-title":"Int. J. Clin. Exp. Med."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719224004402?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719224004402?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T02:20:22Z","timestamp":1742437222000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719224004402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":52,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S1096719224004402"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2024.108556","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical and preclinical insights into high-dose ambroxol therapy for Gaucher disease type 2 and 3: A comprehensive systematic review","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2024.108556","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108556"}}